Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

12/3/2024

Janusmed kön och genus

Janusmed kön och genus – Aclasta

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Zoledronsyra Testmiljö

Zoledronsyra

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Läkemedelsverket. Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation. Läkemedelsverket [www]. [updated 2020-04-30, cited 2020-06-11].

  2. Kaufman JM, Lapauw B, Goemaere S. Current and future treatments of osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2014;28(6):871-84.

  3. Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2018;32(5):759-772.

  4. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.

  5. Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxillofac Surg. 2017;45(9):1493-1502.

  6. Khominsky A, Lim M. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review. Aust Dent J. 2018;63(4):441-454.

  7. Ulmner M, Jarnbring F, Törring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg. 2014;72(1):76-82.

  8. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100-7.

  9. McConeghy KW, Soriano MM, Danziger LH. A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile. Pharmacotherapy. 2016;36(10):1095-1101.

  10. Coloma PM, de Ridder M, Bezemer I, Herings RM, Gini R, Pecchioli S et al. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Osteoporos Int. 2016;27(5):1857-67.

  11. Zometa (zoledronic acid). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-06-15, cited 2020-06-18].

  12. Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23:1083-90.

  13. Hayer PS, Deane AK, Agrawal A, Maheshwari R, Juyal A. Effect of zoledronic acid on fracture healing in osteoporotic patients with intertrochanteric fractures. Int J Appl Basic Med Res. 2017;7(1):48-52.

  14. Magaziner JS, Orwig DL, Lyles KW, Nordsletten L, Boonen S, Adachi JD, Recknor C, Colón-Emeric CS. Subgroup variations in bone mineral density response to zoledronic acid after hip fracture. J Bone Miner Res. 2014;29(12):2545-51.

  15. Gabbert TI, Hoffmeister B, Felsenberg D. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. J Cancer Res Clin Oncol. 2015;141(4):749-58.

  16. Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M et al. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res. 2013;33(9):3917-24.

  17. Wazzan T, Kashtwari D, Almaden WF, Gong Y, Chen Y, Moreb J et al. Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study. Spec Care Dentist. 2018;38(6):356-361.

  18. Jarnbring F, Kashani A, Björk A, Hoffman T, Krawiec K, Ljungman P et al. Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma. Br J Oral Maxillofac Surg. 2015;53(10):1007-11.

  19. Spangeus A, Johansson S, Woisetschlager M. Adherence to and persistence with zoledronic acid treatment for osteoporosis-reasons for early discontinuation . Osteoporos. 2020;15(1):58.

  20. Martín-Merino E, Huerta-Álvarez C, Prieto-Alhambra D, Montero-Corominas D. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos. 2017;12(1):39.

  21. Bor A, Matuz M, Gyimesi N, Biczók Z, Soós G, Doró P. Gender inequalities in the treatment of osteoporosis. Maturitas. 2015;80(2):162-9.

  22. Hernandez RK, Quigley J, Pirolli M, Quach D, Chen KS, Arellano J et al. Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Support Care Cancer. 2014;22(10):2697-705.

  23. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Läkemedelsverket. Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation. Läkemedelsverket [www]. [updated 2020-04-30, cited 2020-06-11].
  2. Kaufman JM, Lapauw B, Goemaere S. Current and future treatments of osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2014;28(6):871-84.
  3. Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2018;32(5):759-772.
  4. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.
  5. Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxillofac Surg. 2017;45(9):1493-1502.
  6. Khominsky A, Lim M. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review. Aust Dent J. 2018;63(4):441-454.
  7. Ulmner M, Jarnbring F, Törring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg. 2014;72(1):76-82.
  8. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100-7.
  9. McConeghy KW, Soriano MM, Danziger LH. A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile. Pharmacotherapy. 2016;36(10):1095-1101.
  10. Coloma PM, de Ridder M, Bezemer I, Herings RM, Gini R, Pecchioli S et al. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Osteoporos Int. 2016;27(5):1857-67.
  11. Zometa (zoledronic acid). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-06-15, cited 2020-06-18].
  12. Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23:1083-90.
  13. Hayer PS, Deane AK, Agrawal A, Maheshwari R, Juyal A. Effect of zoledronic acid on fracture healing in osteoporotic patients with intertrochanteric fractures. Int J Appl Basic Med Res. 2017;7(1):48-52.
  14. Magaziner JS, Orwig DL, Lyles KW, Nordsletten L, Boonen S, Adachi JD, Recknor C, Colón-Emeric CS. Subgroup variations in bone mineral density response to zoledronic acid after hip fracture. J Bone Miner Res. 2014;29(12):2545-51.
  15. Gabbert TI, Hoffmeister B, Felsenberg D. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. J Cancer Res Clin Oncol. 2015;141(4):749-58.
  16. Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M et al. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res. 2013;33(9):3917-24.
  17. Wazzan T, Kashtwari D, Almaden WF, Gong Y, Chen Y, Moreb J et al. Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study. Spec Care Dentist. 2018;38(6):356-361.
  18. Jarnbring F, Kashani A, Björk A, Hoffman T, Krawiec K, Ljungman P et al. Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma. Br J Oral Maxillofac Surg. 2015;53(10):1007-11.
  19. Spangeus A, Johansson S, Woisetschlager M. Adherence to and persistence with zoledronic acid treatment for osteoporosis-reasons for early discontinuation . Osteoporos. 2020;15(1):58.
  20. Martín-Merino E, Huerta-Álvarez C, Prieto-Alhambra D, Montero-Corominas D. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos. 2017;12(1):39.
  21. Bor A, Matuz M, Gyimesi N, Biczók Z, Soós G, Doró P. Gender inequalities in the treatment of osteoporosis. Maturitas. 2015;80(2):162-9.
  22. Hernandez RK, Quigley J, Pirolli M, Quach D, Chen KS, Arellano J et al. Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Support Care Cancer. 2014;22(10):2697-705.
  23. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]